Skip Ribbon Commands
Skip to main content



​​​​​​For information on a research trial, contact the Research Office at 469.814.4720 or​



Principal Investigator: Robert L. Smith, II, MD

Evaluate the efficacy and safety of performing tricuspid valve (TV) repair in patients undergoing mitral valve surgery with either moderate tricuspid regurgitation (TR) or less-than-moderate TR with tricuspid annular dilation.

HeartMate III™

Principal Investigators: Shelley Hall​, MD

Evaluate the safety and efficacy of injecting MPCs (150 million dose) into the native myocardium of LVAD recipients. The secondary objectives are to explore the functional and psychological effects of injecting MPCs (150 million dose) into the native myocardium of LVAD recipients.

Hybrid Coronary

Principal Investigators: Robert L. Smith, II, MD / Molly Szerlip, MD

The purpose of this study is to evaluate the effectiveness and safety of hybrid coronary revascularization (HCR) compared to multi-vessel percutaneous cardiac intervention (PCI) with metallic drug-eluting stents (DES) in patients with multi-vessel coronary artery disease (CAD) involving the left anterior descending (LAD) and/or left main (LM) arteries.

Post MRV Afib

Principal Investigator: James R. Edgerton, MD

Assessment of the incidence of atrial fibrillation (Afib) events after discharge in patients with isolated post-mitral valve/replacement or post-mitral valve repair/replacement with tricuspid valve repair/replacement.​


Principal Investigators: J. Michael DiMaio, MD / Kelley Hutcheson, MD

To demonstrate the safety and effectiveness of the VEST for its intended use: Limiting intimal hyperplasia by providing permanent support to saphenous vein grafts which are being used as conduits in patients who undergo coronary artery bypass grafting procedures as treatment for coronary atherosclerotic disease.